Douglas K. Bratton - 31 Dec 2024 SCHEDULE 13G/A Report for Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share (AQST)

Filing Manager: Douglas K. Bratton
Reporting Manager: BRATTON DOUGLAS K
Security: Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share
Symbol: AQST
Shares outstanding: 90,787,694 shares
Disclosed Ownership: 10,077,434 shares
Ownership: 11%
Form type: SCHEDULE 13G/A
Filing time: 13 Feb 2025, 11:38:04 UTC
Date of event: 31 Dec 2024
SEC: View on sec.gov

Key filing fact

Douglas K. Bratton disclosed 11% ownership in Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share (AQST) on 31 Dec 2024.

Key facts

Douglas K. Bratton filed SCHEDULE 13G/A for Aquestive Therapeutics, Inc. Common Stock, Par Value $0.001 Per Share (AQST).
Disclosed ownership: 11%.
Date of event: 31 Dec 2024.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Reporting persons

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name	Ownership	Shares Owned	sole voting power	Signature	Title
BRATTON DOUGLAS K	11%	10,077,434	10,023,384	Douglas K. Bratton	Individual
MonoLine RX II, L.P.	3.8%	3,468,747	3,468,747	John Cochran	Vice President of General Partner of General Partner
MonoLine RX III, L.P.	2.9%	2,657,943	2,657,943	John Cochran	Vice President of General Partner of General Partner
MonoLine RX, L.P.	1.9%	1,688,639	1,688,639	John Cochran	Vice President of General Partner of General Partner
MonoLine Partners, L.P.	2.1%	1,948,578	1,948,578	John Cochran	Vice President of General Partner of General Partner
MonoSol Rx Genpar, L.P.	0.1%	47,051	47,051	John Cochran	Vice President of General Partner

CIK / CUSIP context first

Broader feeds